Hybridoma Cell Line D8H21, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex

Hybridoma Cell Line D8H21, as described in Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13856-61 and developed in the laboratory of Dr. Ronald Germain.

Potential Commercial Applications:		Competitive Advantages:
A research material that can be used in the development of assays, validation of products or in quality control.		Speed up product development with NIH developed material that has already been tested and validated.

Inventors:

Ronald Germain (NIAID)  ➽ more inventions...


Intellectual Property:
Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-039)

Publications:
Zhong G, et al. PMID 9391117

Licensing Contact:
Daniel Lee, J.D.
Email: daniel.lee5@nih.gov
Phone: 301-761-6327

OTT Reference No: B-021-1999-0
Updated: Dec 4, 2017